Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Dec 18;8(1):e925.
doi: 10.1212/NXI.0000000000000925. Print 2021 Jan.

N2 year in review

Josep Dalmau, Marinos C Dalakas  1 , Dennis L Kolson  1 , Friedemann Paul  1 , Scott S Zamvil  1
Affiliations
Editorial

N2 year in review

Josep Dalmau et al. Neurol Neuroimmunol Neuroinflamm. .
No abstract available

PubMed Disclaimer

References

    1. Berger JR, Brandstadter R, Bar-Or A. COVID-19 and MS disease-modifying therapies. Neurol Neuroimmunol Neuroinflamm 2020;7:e761 doi: 10.1212/NXI.0000000000000761. - DOI - PMC - PubMed
    1. Barzegar M, Mirmosayyeb O, Nehzat N, et al. . COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neurol Neuroimmunol Neuroinflamm 2020;7:e753 doi: 10.1212/NXI.0000000000000753. - DOI - PMC - PubMed
    1. Fan M, Qiu W, Bu B, et al. . Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm 2020;7:e787 doi: 10.1212/NXI.0000000000000787. - DOI - PMC - PubMed
    1. Parrotta E, Kister I, Charvet L, et al. . COVID-19 outcomes in MS: observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center. Neurol Neuroimmunol Neuroinflamm 2020;7:e753 doi: 10.1212/NXI.0000000000000753. - DOI - PMC - PubMed
    1. Bowen JD, Brink J, Brown TR, et al. . COVID-19 in MS: initial observations from the Pacific Northwest. Neurol Neuroimmunol Neuroinflamm 2020;7:e783 doi: 10.1212/NXI.0000000000000783. - DOI - PMC - PubMed

Publication types